JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Director James N. Topper of NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS) recently purchased 471 ordinary shares of the company. The transactions, which occurred on August 11, 2025, involved a purchase at a weighted average price of $23.9787, resulting in a total value of $11293. The prices for these shares ranged from $23.91 to $24.00. The purchase comes as NAMS trades near its 52-week high of $27.29, with the stock showing impressive momentum, up nearly 29% over the past six months. According to InvestingPro data, analysts maintain a strong buy consensus with price targets reaching as high as $45.26.
Following the transaction, Topper directly holds 3,026,604 shares through Frazier Life Sciences X, L.P., and 3,801,000 indirectly through Frazier Lifesciences Sponsor LLC. The company, currently valued at $2.9 billion, maintains a strong balance sheet with more cash than debt and excellent liquidity ratios. For deeper insights into insider trading patterns and comprehensive financial analysis, check out the detailed NAMS Pro Research Report, available exclusively on InvestingPro.
In other recent news, NewAmsterdam Pharma has reported promising results from its BROADWAY clinical trial, where its experimental drug obicetrapib significantly reduced plasma p-tau217, a key biomarker of Alzheimer’s disease. This development is part of a broader effort by the company to educate investors on obicetrapib’s potential effects on various conditions, including atherosclerotic cardiovascular disease, diabetes, and Alzheimer’s disease. Piper Sandler has reiterated its Overweight rating on NewAmsterdam Pharma, maintaining a positive outlook on obicetrapib, and TD Cowen has also reiterated a Buy rating as the company gears up for the PREVAIL data release. Meanwhile, Goldman Sachs has initiated coverage with a Neutral rating, citing an extended timeline for the Phase 3 PREVAIL cardiovascular outcomes trial results expected in late 2026. Additionally, NewAmsterdam Pharma has updated its employment agreement with Chief Scientific Officer Dr. John Kastelein, which includes provisions for compensation if his employment is terminated without cause.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.